A phase 1 clinical trial of JADE-301
Latest Information Update: 19 Jan 2026
At a glance
- Drugs JADE 301 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
Most Recent Events
- 19 Jan 2026 New trial record
- 05 Jan 2026 According to a Jade Biosciences media release, company plans a phase I trial for Autoimmune disorders in the first half of 2027 and further details of JAE-301 are expected to be disclosed in the second half of 2026.